Nephrogenic systemic fibrosis: A mysterious disease in patients with renal failure - Rrole of gadolinium-based contrast media in causation and the beneficial effect of intravenous sodium thiosulfate

Clinical Journal of the American Society of Nephrology

Volumn 2, Issue 2, 2007, Pages 258-263

  Yerram, Preethi ^a   Saab, Georges ^a   Karuparthi, Poorna R ^a   Hayden, Melvin R ^a   Khanna, Ramesh ^a  

^a University of Missouri   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONTRAST MEDIUM; GADODIAMIDE; GADOLINIUM PENTETATE; SODIUM THIOSULFATE; THIOSULFATE;

ADULT; ARTICLE; CASE REPORT; CHEMICALLY INDUCED DISORDER; FEMALE; FIBROSIS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY FAILURE;

ADULT; CONTRAST MEDIA; FEMALE; FIBROSIS; GADOLINIUM DTPA; HUMANS; INJECTIONS, INTRAVENOUS; KIDNEY FAILURE; THIOSULFATES;

EID: 34249818373     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.03250906     Document Type: Article

References (25)

1. Cowper SE, Robin HS, Steinberg SM, Su LD, Gupta S, LeBoit PE: Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet 356: 1000-1001, 2000
2. Mendoza F, Artlett C, Sandorfi N, Latinis K, Piera-Velazquez S, Jimenez S: Description of 12 cases of nephrogenic fibrosing dermopathy and review of the literature. Semin Arthritis Rheum 35: 238-249, 2006
3. Ting WW, Stone MS, Madison KC, Kurtz K: Nephrogenic fibrosing dermopathy with systemic involvement. Arch Dermatol 139: 903-906, 2003
4. Grobner T: Gadolinium: A specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis. Nephrol Dial Transplant 21: 1104-1108, 2006
5. Marckmann P, Skov L, Rossen K, Dupont A, Damholt MB, Heaf JG, Thomsen HS: Nephrogenic systemic fibrosis: Suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging J Am Soc Nephrol 17: 2359-2362, 2006
6. FDA: Public Health Advisory: Gadolinium-Containing Contrast Agents for Magnetic Resonance Imaging (MRI) - Omniscan, OptiMARK, Magnevist, ProHance, and MultiHance, Washington, DC, FDA, 2006
7. Boyd A, Zic J, Abraham J: Gadolinium deposition in nephrogenic fibrosing dermopathy. J Am Acad Dermatol 56: 27-30, 2007
8. High W, Ayers R, Chandler J, Zito G, Cowper S: Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 56: 21-26, 2007
9. Runge VM: Safety of approved MR contrast media for intravenous injection. J Magn Reson Imaging 12: 205-213, 2000
10. Townsend RR, Cohen DL, Katholi R, Swan SK, Davies BE, Bensel K, Lambrecht L, Parker J: Safety of intravenous gadolinium (Gd-BOPTA) infusion in patients with renal insufficiency. Am J Kidney Dis 36: 1207-1212, 2000
11. Joffe P, Thomsen HS, Meusel M: Pharmacokinetics of gadodiamide injection in patients with severe renal insufficiency and patients undergoing hemodialysis or continuous ambulatory peritoneal dialysis. Acad Radiol 5: 491-502, 1998
12. Mann JS: Stability of gadolinium complexes in vitro and in vivo. J Comput Assist Tomogr 17[Suppl 1]: S19-S23, 1993
13. Jimenez SA, Artlett CM, Sandorfi N, Derk C, Latinis K, Sawaya H, Haddad R, Shanahan JC: Dialysis-associated systemic fibrosis (nephrogenic fibrosing dermopathy): Study of inflammatory cells and transforming growth factor beta1 expression in affected skin. Arthritis Rheum 50: 2660-2666, 2004
14. Ortonne N, Lipsker D, Chantrel F, Boehm N, Grosshans E, Cribier B: Presence of CD45RO+ CD34+ cells with collagen synthesis activity in nephrogenic fibrosing dermopathy: A new pathogenic hypothesis. Br J Dermatol 150: 1050-1052, 2004
15. Swaminathan S, Ahmed I, McCarthy J, Albright R, Pittelkow M, Caplice N, Griffin MD, Leung N: Nephrogenic fibrosing dermopathy and high-dose erythropoietin therapy. Ann Intern Med 145: 234-235, 2006
16. Neuwelt EA, Brummett RE, Doolittle ND, Muldoon LL, Kroll RA, Pagel MA, Dojan R, Church V, Remsen LG, Bubalo JS: First evidence of otoprotection against carboplatin-induced hearing loss with a two-compartment system in patients with central nervous system malignancy using sodium thiosulfate. J Pharmacol Exp Ther 286: 77-84, 1998
17. Viallet NR, Blakley BW, Begleiter A, Leith MK: Effect of sodium thiosulphate and cis-diamminedichloroplatinum on FADU tumour cells in nude mice. J Otolaryngol 34: 371-373, 2005
18. Brucculeri M, Cheigh J, Bauer G, Serur D: Long-term intravenous sodium thiosulfate in the treatment of a patient with calciphylaxis. Semin Dial 18: 431-434, 2005
19. Hayden MR, Tyagi SC, Kolb L, Sowers JR, Khanna R: Vascular ossification-calcification in metabolic syndrome, type 2 diabetes mellitus, chronic kidney disease, and calciphylaxis-calcific uremic arteriolopathy: The emerging role of sodium thiosulfate. Cardiovasc Diabetol 4: 4, 2005
20. Edsall LC, English JC 3rd, Patterson JW: Calciphylaxis and metastatic calcification associated with nephrogenic fibrosing dermopathy. J Cutan Pathol 31: 247-253, 2004
21. Cowper SE, Su LD, Bhawan J, Robin HS, Leboit PE: Nephrogenic fibrosing dermopathy. Am J Dermatopathol 23: 383, 2001
22. Streams BN, Liu V, Liegeois N, Moschella SM: Clinical and pathologic features of nephrogenic fibrosing dermopathy: A report of two cases. J Am Acad Dermatol 48: 42-47, 2003
23. Swartz RD, Crofford LJ, Phan SH, Ike RW, Su LD: Nephrogenic fibrosing dermopathy: A novel cutaneous fibrosing disorder in patients with renal failure. Am J Med 114: 563-572, 2003
24. Cowper SE: Nephrogenic fibrosing dermopathy: The first 6 years. Curr Opin Rheumatol 15: 785, 2003
25. Hayden M, Tyagi S: Neural redox stress and remodeling in metabolic syndrome, type 2 diabetes mellitus, and diabetic neuropathy. Med Sci Monit 10: RA291-RA307, 2004